Positive results announced from planned interim analysis of phase 3 ALPINE trial comparing zanubrutinib against ibrutinib in adults with relapsed or refractory CLL or small lymphocytic lymphoma

In interim analysis (n=415 of 652 followed for ≥12 months), zanubrutinib, a BTK inhibitor met the primary endpoint of non-inferiority in objective response rate (p<0.0001). Data pertaining to progression-free survival in the 652 patients, were immature at the data cutoff.

Source:

Biospace Inc.